Esperion Therapeutics (ESPR) investor relations material

Executive summary

• Net loss for Q1 2026 was $25.2 million, an improvement from $40.5 million in Q1 2025, driven by higher product and collaboration revenues and lower R&D expenses.

• Product sales and collaboration revenues increased year-over-year, reflecting growth in NEXLETOL and NEXLIZET prescriptions and expanded international partnerships.

• Completed the acquisition of Corstasis, adding Enbumyst, an FDA-approved nasal spray loop diuretic, to the portfolio.

• Entered into a definitive merger agreement to be acquired by Essence Parent Inc., with closing expected in Q3 2026.

Financial highlights

• Q1 2026 product sales, net: $43.4 million (up from $34.9 million in Q1 2025).

• Q1 2026 collaboration revenue: $36.7 million (up from $30.1 million in Q1 2025).

• Cost of goods sold: $34.6 million (up from $31.5 million in Q1 2025).

• Research and development expenses: $9.0 million (down from $12.6 million in Q1 2025).

• Selling, general and administrative expenses: $43.1 million (flat year-over-year).

• Interest expense: $19.8 million (up slightly from $19.4 million in Q1 2025).

• Cash and cash equivalents as of March 31, 2026: $156.2 million.

Outlook and guidance

• Management expects continued operating losses in the near term as commercialization and integration of new products continue.

• Current cash, expected product sales, and collaboration revenues are anticipated to fund operations for the foreseeable future.

• The merger with Essence Parent Inc. is expected to close in Q3 2026, subject to shareholder and regulatory approvals.